بررسی تأثیر ژل واژینال بابونه بر نشانههای ذهنی آتروفی واژن در زنان یائسه: یک کارآزمایی بالینی شاهددار تصادفی شده

نوع مقاله: اصیل پژوهشی

نویسندگان

1 کارشناس ارشد مامایی، مرکز تحقیقات آندروپوز منوپوز، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.

2 استادیار گروه مامایی، مرکز تحقیقات آندروپوز منوپوز، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.

3 استاد گروه داروسازی، مرکز تحقیقات گیاهان دارویی، دانشکده داروسازی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.

4 مربی آمار و اپیدمیولوژی، دانشکده بهداشت، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران.

5 استادیار گروه زنان و مامایی، مرکز تحقیقات باروری- ناباروری و پریناتولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران

چکیده

مقدمه: آتروفی واژن با کمبود استروژن در زنان یائسه اتفاق می­افتد و کیفیت زندگی زنان یائسه را تحت تأثیر قرار می­دهد. مطالعه حاضر با هدف تعیین تأثیر ژل واژینال بابونه بر نشانه­های ذهنی آتروفی واژن در زنان یائسه انجام شد.
روش‌کار: این مطالعه کارآزمایی بالینی دوسوکور در سال 1397 بر روی 96 زن یائسه دارای نشانه­های ذهنی آتروفی واژن در مرکز بهداشتی درمانی شماره یک شهر گتوند انجام شد. افراد به‌صورت تصادفی در سه گروه 32 نفره جهت دریافت ژل واژینال بابونه 5%، کرم واژینال استروژن کنژوگه و ژل دارونما به‌مدت 12 هفته قرار گرفتند. نشانه­های ذهنی آتروفی شامل: سوزش، خارش، درد هنگام مقاربت و احساس خشکی واژن با استفاده از پرسشنامه خودسنجی 4 درجه­ای لیکرت قبل از مداخله و در هفته­های 2، 6 و 12 بعد از درمان بررسی شد. تجزیه و تحلیل داده­ها با استفاده از نرم‌افزار آماری SPSS (نسخه 22) و آزمون­های آنالیز واریانس یک‌طرفه، کروسکال والیس، کای دو و فریدمن انجام شد. میزان p کمتر از 05/0 معنی‌دار در نظر گرفته شد.
یافته‌ها: نشانه‌های ذهنی آتروفی واژن در گروه‌های درمانی ژل واژینال بابونه و کرم واژینال استروژن کنژوگه در مقایسه با گروه دارونما (ژل واژینال دارونما) به‌صورت معنی­داری بهبود یافت (001/0>p)، اما بین گروه استروژن واژینال کنژوگه و گروه ژل واژینال بابونه تفاوت آماری معنی­داری مشاهده نشد.
نتیجه‌گیری: ژل واژینال بابونه مشابه کرم استروژن کنژوگه سبب کاهش نشانه‌های ذهنی آتروفی واژن در زنان یائسه می‌گردد.

کلیدواژه‌ها


عنوان مقاله [English]

Evaluation of the effect of Chamomile vaginal gel on Subjective symptoms of vaginal atrophy in postmenopausal women: A randomized clinical controlled trial

نویسندگان [English]

  • Zahra Bosak 1
  • Mina Iravani 2
  • Eskandar Moghimipour 3
  • Mohammad Hossein Haghighizadeh 4
  • Parivash Jelodarian 5
1 MSc Student of Midwifery, Menopause Andropause Research Center, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 PhD in Reproductive Health, Assistant Professor of Midwifery Department, Menopause Andropause Research Center, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 PhD in Pharmaceutics, Professor of Pharmaceutics, Department of Pharmaceutics, School of Pharmacy, Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Lecturer in Biostatistics Department, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
5 Gynecologist, Assistant Professor of Obstetrics and Gynecology Department, Fertility Infertility and Perinatology Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
چکیده [English]

Introduction: Vaginal atrophy is caused by estrogen deficiency in postmenopausal women and affects their quality of life. The present paper aimed to investigate the effects of chamomile vaginal gel on the subjective symptoms of vaginal atrophy in postmenopausal women.
Methods: This double-blind clinical trial study was performed on 96 postmenopausal women with the subjective symptoms of vaginal atrophy in the No. 1 healthcare center in Gotvand. The subjects were randomly divided into three groups of 32 cases to receive 5% vaginal chamomile gel, conjugated vaginal estrogen cream, and placebo gel for 12 weeks. Subjective symptoms of atrophy, including irritation, itching, pain during intercourse, and vaginal dryness, were assessed using a 4-point Likert self-report questionnaire before the intervention and at 2, 6, and 12 weeks after the treatment. The data were analyzed using SPSS statistical software (version 22) and one-way analysis of variance, Kruskal-Wallis, Chi-square, and Friedman tests. P-value less than 0.05 was considered significant.
Results: Subjective symptoms of vaginal atrophy improved significantly in the chamomile gel and conjugated vaginal estrogen cream treatment groups, compared with those of the placebo group (i.e., placebo vaginal gel) (P<0.001). However, there was no significant difference between the conjugated vaginal estrogen and chamomile vaginal gel groups.
Conclusion: Similar to the conjugated estrogen cream, the chamomile vaginal gel mitigated the subjective symptoms of vaginal atrophy; therefore, it can be useful in women with vaginal atrophy.

کلیدواژه‌ها [English]

  • Chamomile
  • vaginal gel
  • Atrophic symptoms
  • Menopause
  1. Asadi M, Jouyandeh Z, Nayebzadeh F. Prevalence of menopause symptoms among Iranian women. J Fam Reprod Health 2012; 6(1):1-3.
  2. Novak E, Berek JS. Berek & Novak's gynecology. Philadelphia: Lippincott Williams & Wilkins; 2007. P. 1063-74.
  3. Nouhjah S, Mohammad JR, Latifi SM. The mean age of menopause and its determinant factors: a cross-sectional study in Ahwaz 2001-2002. Jundishapur Sci Med J 2005; 4(4):216-22.
  4. Shohani M, Rasouli FA, HajiAmiry P, HasanpoorDehkordi A, Mahmoudi MA. Evaluation of the urogenital problems of menopausal woman referred to the health care centers of Ilam, Iran. Hormozgan Med J 2009; 13(3):189-96. (Persian).
  5. Labrie F, Cusan L, Gomez G, Cote I, Berube R, Belanger P, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008; 111(3-5):178-94.
  6. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med pharmacol Sci 2008; 12(6):411-6.
  7. Woods NF, Mitchel ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women’s lives. Am J Med 2005; 118(12B):14-24.
  8. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marre GB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginal used in postmenopausal women with genital atrophy. Arzneimitteforschung 2006; 56(3):230-8.
  9. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Society. Menopause 2013; 20(9):888-902.
  10. Samuels JB, Garcia MA. Treatment to external labia and vaginal canal with co2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesth Surg J 2019; 39(1):83-93.
  11. Gastiglione C, Licciardello O, Rampullo A, Campione C. Representation of future changes in menopausal Women. Proc Soc Behav Sci 2014; 116:499-7.
  12. Golmakani N, Parnan Imamverdikhan A, Hasanzadeh Mofrad M, Sajjadi Tabasi A, Sharifi Sistani N, Taghi Shakeri M. The comparison of clinical and laboratory indexes for diagnosis of vaginal atrophy in postmenopausal women. Iran J Obstet Gynecol Infertil 2015; 17(105):10-7. (Persian).
  13. Nilsson K, Ribsberg B, Heimer G. The vaginal epithelium in the post menopause--cytology, histology and PH as methods of assessment. Maturitas 1995; 21(1):51-6.
  14. Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther 2011; 89(1):129-32.
  15. Taavoni S, Unesie Kafshgiry M, Shahpoorian F, Mahmoudie M. Hormone replacement therapy: post-menopausal sex life and attitudes towards sex. Psychogeriatrics 2005; 5(1):9-14.
  16. Jassim GA. Strategies for managing hot flashes. J Fam Pract 2011; 60(6):333-9.
  17. Hatami L, Estakhr J. The effects of hydroalcoholic extract of matricaria recutita on the hormonal pituitary-testis axis and testis tissue changes of mature male rats. J Fasa Univ Med Sci 2013; 3(1):56-62. (Persian).
  18. Azizi M. Study of four improved cultivars of Matricaria chamomilla L. in climatic condition of Iran. Iran J Med Arom Plants 2006; 22(4):386-96. (Persian).
  19. Abdullahzadeh M, Naji SA. The effect of Matricaria chamomilla on sleep quality of elderly people admitted to nursing homes. Iran J Nurs 2014; 27(89):69-79.
  20. Kesmati M, Raei H, Zadkarami M. Effect of Matricaria chamomilla hydro alcoholic extract on locomotor activity in the presence and absence of sex glands in male and female adult mice. Shahid Chamran Univ J Sci 2007; 17(8):73-83. (Persian).
  21. Abbasinia H, Alizadeh Z, Vakilian K, Jafari Z, Matoyripoor P, Ranjbaran M. Effect of chamomile extract on sleep disorder in menopausal women. Iran J Obstet Gynecol Infertil 2016; 19(20):1-7. (Persian).
  22. Seyyedi SA, Sanatkhani M, Pakfetrat A, Olyaee P. The therapeutic effects of chamomile tincture mouthwash on oral aphthae: a randomized clinical trial. J Clin Exp Dent 2014; 6(5):535-8.
  23. Sadeghi M, Abbaspoor Z, Namjouyan F, Cheraghian B. Effect of Glycyrrhiza glabra vaginal cream on the mental symptoms of vaginal atrophy in postmenopausal women. Iran J Obstet Gynecol Infertil 2018; 21(4):53-61. (Persian).
  24. Yaralizadeh M, Abedi P, Najar S, Namjoyan F, Saki A. Effect of foeniculum vulgare (fennel) vaginal cream on vaginal atrophy in postmenopausal women: a double-blind randomized placebo controlled trial. Maturitas 2016; 84:75-80.
  25. Hosseinzadeh P, Ghahiri A, Daneshmand F, Ghasemi M. A comparative study of vaginal estrogen cream and sustained-release estradiol vaginal tablet (Vagifem) in the treatment of atrophic vaginitis in Isfahan, Iran in 2010-2012. J Res Med Sci 2015; 20(12):1160-5.
  26. SuwanveshN, Manonai J, Sophonsritsuk A, Cherdshewasart W. Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women. Menopause 2016; 24(2):210-5.
  27. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009; 16(4):735-41.
  28. Novak E. Berek & Novak’s gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. P. 1323-38.
  29. Karimi Afshar H. Clinical evaluation of bucoadhesive paste containing trigonella foenum graecum liquid extract in comparison to control. [Doctoral Dissertation]. Kerman, Iran: School of Pharmacy, Kerman University of Medical Sciences; 2015. (Persian).
  30. Skala CE, Petry IB, Albrich S, Puhl A, Naumann G, Koelbl H. The effect of genital and lower urinary tract symptoms on steroid receptor expression in women with genital prolapse. Int Urogynecol J 2011; 22(6):705-12.
  31. Lima SM, Bernardo BF, Yamada SS, Reis BF, da Silva GM, Galvão MA. Effects of Glycine Max (L.) merr. Soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial. Maturitas 2014; 78(3):205-11.
  32. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015; 18(2):260-9.